What is up with Nonoxynol-9? Global Campaign for Microbicides www.global-campaign.org.

Slides:



Advertisements
Similar presentations
What does sexual & reproductive health have to do with clinical trials? Providing contraception & reproductive health care helps.
Advertisements

Comparison of STD Prevalence by Reported Condom Use Errors in 100% Condom Users of an Urban STD Clinic Judith C. Shlay, MD, MSPH Jennifer Landrigan, MHS.
The Connection Between STDs and HIV
STD Fact or Fiction.
Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.
Working world wide against HIV for the health and human rights of men who have sex with men Working world wide against HIV for the health and human rights.
Session 2 Key Messages You can be infected with an STD and have no symptoms. It can take years for symptoms of some STDs to develop. Having an STD raises.
HIV True or False Module HIV/AIDS Activity 2: HIV:True or False.
HIV CENTER for Clinical and Behavioral Studies MAIN POINTS ACKNOWLEDGMENTS This research was supported by a NIMH grant (R ; PI, Alex Carballo-Diéguez,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
High Sexual Risk But Low HIV Prevalence Among Asian And Pacific Islander (API) Men Who Have Sex With Men (MSM) Kyung-Hee Choi Center for AIDS Prevention.
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
Rectal Microbicides: The Basics Date, Location Your Name, Organization.
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.
1 Are Lubes Safe for Rectal Use? Next Steps for Researchers and Advocates Marc-André LeBlanc, Jim Pickett, Charlene Dezzutti, Edward Fuchs, Pamina Gorbach,
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
Rectal Microbicides: The Basics October 2008, ESM Marc-André LeBlanc, GCM.
Contraception Today: What’s new? Carol E. Peterson, MS, RN Wyoming Health Council.
Rectal Microbicides: New Hope for Non-Condom Prevention of HIV and other STDs.
Design of Phase III Microbicide Trials: Choice of Control Group August 20, 2003 Rosalie Dominik, DrPH Director of Biostatistics Institute for Family Health.
HIVTools Research Group The Public Health Impact of Microbicides Charlotte Watts Ph.D.
Context and Association of Meth Use and Sexual Risk Behavior David W. Purcell, JD, PhD Prevention Research Branch Division of HIV/AIDS Prevention, NCHHSTP,
Northwest Portland Area Indian Health Board
Responding to Frequently Asked Questions Lori Heise, Director
National Working Group on Microbicides Meeting of NWG subgroup on Rectal Microbicides Advocacy in India Organized by The National Working Group on Microbicides.
Sexually transmitted diseases. Increasing due to: n Increasing sexual activity n Multiple sexual partners n Use of birth control pills – Increases the.
DEVELOPING DUAL COMPARTMENT MPTS THAT WORK UP FRONT AND FROM BEHIND José Fernández Romero Population Council September 9, 2015.
Pregnancy and Sexually Transmitted Infections Facts About Teens and Sexual Activity.
STDs among Men who Have Sex with Men (MSM), San Francisco 2007—2010 STD Prevention and Control Services San Francisco Department of Public Health.
CONTRACEPTIVES. How Pregnancy Happens  Review  Ejaculate gets in her vagina or on her vulva  Unprotected vaginal intercourse  Can take up to six days.
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
What sexually transmitted diseases can I get? © Robert J. Atkins, Ph.D.
Rectal Microbicides: New Hope for HIV and STD Prevention.
Microbicides: What will they do? What will they be like? What needs to be done? Richard A. Cone Johns Hopkins University ReProtect, LLC (“BufferGel™” &
Adolescent Reproductive Health. Adolescent Reproductive Health, USA 870,000 teens became pregnant in 1997 Just under 500,000 births 75-80% teen moms unmarried.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.
National Working Group on Microbicides Rectal microbicides: The political landscape Ananthy Thambinayagam, MPH Global Campaign for Microbicides Rectal.
National Working Group on Microbicides RECTAL MICROBICIDES RESEARCH CURRENT STATUS & CHALLENGES Dr. Badri N. Saxena, M.D., F.A.M.S. Professor, Centre for.
The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.
Partnering to Promote Female-controlled HIV Prevention Methods Matthews J, Becker J, Massey C, Jacobsen J, Patel B Ibis Reproductive Health, International.
Rectal microbicides, where are we? Kim Mulji Naz Foundation International.
JOSEPH O’REILLY Deputy Chief Executive REBEKAH WEBB Policy Officer IN COLLABORATION WITH THE GLOBAL CAMPAIGN FOR MICROBICIDES IS THERE AN INVISIBLE CONDOM.
Implications of Anal Intercourse and Rectal use of Products in Vaginal Microbicide Trials Ian McGowan MD PhD FRCP.
STIs (sexually transmitted infections) in the geriatric population
A Jo Robinson, Terrence Higgins Trust in cooperation with the Global Campaign for Microbicides Topical.
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
SEXUAL BEHAVIOR HIV AND OTHER STD PREVENTION Family Life and Sexuality: Methods of Birth Control Erika Frank.
Chapter 13 Personal Wellness Sexually Transmitted Diseases Pages
Rectal microbicides advocacy Issues, work and collaboration Kim Mulji UK rectal microbicides working group.
A people-centred perspective Dr Roger Tatoud Imperial College London IRMA Global Teleconference 4 December 2009.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Microbicide Acceptability: What We Know Elizabeth McGrory Population Council May 12, 2002.
What are you into? The role of social networking platforms in HIV risk behavior Darren Whitfield, MSW, Doctoral Student University of Denver, Graduate.
Microbicides: New Hope for Prevention of HIV and other STIs Your name here
Adapted and reproduced with permission from Alberta Health Services
Information about HIV Prevention Options
Module 4 (e) Pregnancy and Breast Feeding
On behalf of The MTN-020/ASPIRE Study Team
Sexually transmitted diseases
Ring Frequently Asked Questions
Adapted and reproduced with permission from Alberta Health Services
A study of high risk African American women, 15 to 21 years of age
Non-Viral STD of Major significance
Content Vocabulary abstinence monogamous safer-sex strategies
Secondary Prevention.
A public cervix announcement: CERVICAL BARRIERS in seven minutes
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
Presentation transcript:

What is up with Nonoxynol-9? Global Campaign for Microbicides

Background on Nonoxynol-9 Nonoxynol-9 is the active ingredient in most over the counter spermicides 'Film 70 mg 'Foams mg 'Suppositories 100 mg 'Gels mg 'Sponge1000 mg

N-9 also added to Some over-the-counter sexual lubricants KY Plus (with N-9)2% by volume ForPlay  (with N-9)1% by volume Some lubricated condoms mg (US) mg (outside US)

History of N-9 testing Early testing proceeded in the hope that an existing product might prove effective against HIV Previous human studies suggested that it offered some protection against gonorrhea, chlamydia, & HIV (based on epidemiological studies not RCTs) Early clinical trials done with different products in different populations showed contradictory results  some suggested that N-9 could increase HIV risk  some suggested that low dose products could decrease risk So work on lower dose N-9 products continued

UNAIDS trial reveals no protection for Advantage-S Preliminary data out of Durban in July, showed that sex workers using Advantage-S gel (52.5 mg of N-9) had higher rates of HIV sero-conversion than those using placebo, 3possibly due to increased vaginal disruption caused by the N-9 These data are difficult to generalize because of the variation in dose and formulation among various N-9 products Sex workers had on average 3.7 clients per day

Nonoxynol-9 and rectal sex David Phillips et al found that even low doses of N-9 caused massive sloughing of the rectal epithelium (n=4 people). Findings duplicated in large sample Rectal epithelium heals quickly – less than 8 hours Damage associated with rectal use of N-9 is far more extensive than observed with vaginal use of products Rectal exposure to N-9 increases transmission of HSV in mice and monkeys

Who is at risk? In US, more women than men have receptive anal sex % of heterosexual women in the US had anal sex in the last year (Gross et al, 2000) In one US study, 32% of high-risk women participants reported anal sex in past six months (Gross et al 2000) In a Chinese study of 1300 people from 41 cities, nearly 70% of men and women reported engaging in anal intercourse (Burton 1990).

What happened next? Work with N-9 as a potential microbicide ceased CDC issued guidance saying that N-9 should not be recommended for HIV prevention or included in “hierarchical” messages and N-9 lubricated condoms should no longer be recommended WHO held an expert consultation in October 2001 to further refine public health messages around N- 9 and N-9 lubricated condoms

WHO Expert Group Findings N-9 does not provide protection against HIV or bacterial STDs such as gonorrhea and chlamydia. When used frequently in the vagina (more than once a day*), N-9 products cause epithelial disruption that may increase the risk of HIV infection. Women who are at risk of HIV or have multiple acts of intercourse in a day should use a different form of contraception. Spermicides containing N-9 remain a safe contraceptive option for women who are not at risk of HIV

Findings (continued) Under no circumstances, should N-9 containing products be used rectally. There is no evidence that condoms lubricated with N-9 are more effective in preventing pregnancy or infection when used vaginally than condoms lubricated with silicone. Therefore N-9 condoms should no longer be promoted. (Nonetheless, a condom with N-9 is still better than no condom at all)

Public Health Challenges The idea that N-9 offers “extra protection” from HIV is very entrenched Big confusion regarding N-9 products and messages Complicated message to impart: 3N-9 does not work for STD/HIV prevention 3Should NOT be used rectally – may increase risk 3Safe to use vaginally for pregnancy prevention if you are not at risk of HIV and use infrequently

Gay men are still seeking out N-9 Among a diverse sample of 573 MSM in San Francisco, 67% had used N-9 in the past year This was after CDC issued warnings and the San Francisco DOH undertook outreach activities Among those who had used N-9 in the last year: 3 41% used it without a condom because they thought the N-9 might be protective 3 74% used it with a condom for “added protection”

Origins of N-9 Call Global Campaign for Microbicides responded because data on rectal use of N-9 isn’t being heard Formed partnership with GAAN to develop strategy to reduce risks due to rectal exposure to N-9 Simultaneous goal to build stronger partnerships with gay/lesbian and mainstream AIDS groups around need for rectal microbicide research Created working group of scientists and representatives of key constituent groups to develop strategy

Consensus message New data reveal that when used rectally, even small doses of nonoxynol-9 can increase risk of HIV transmission When used consistently and correctly, lubricated condoms give excellent protection against pregnancy and HIV, even without the addition of Nonoxynol-9.; Adding N-9 to condom lubrication may not provide any additional protection against pregnancy Therefore, we are asking manufacturers to help eliminate this public health risk by phasing out the addition of N-9 to condoms and sexual lubricants

Logic behind Call Two pronged strategy for change: 3public education to “undo” entrenched messages re: N-9 3phasing out source of risk by removing N-9 from products used rectally N-9 in lubricant benefits no one, therefore it should be phased out N-9 on condoms can harm those using it rectally. It has no proven benefit in terms of birth control. Therefore, it should be eliminated. N-9 contraceptive products are the only user-controlled, non-hormonal birth control methods available in the US. Women need this option. They also need education about its benefits and risks.

Global Campaign Response Conversations with manufacturers Call to Discontinue Use Letter to FDA re: labeling etc. Efforts to pressure CDC to fund major education effort (via consortium of groups like NFPRHA, ASHA, etc). Follow up efforts re: safety testing of existing lubricants Coalition building for microbicides

What does this mean for microbicides in general? Recent news about N-9 has led some people to think that developing a safe, effective microbicide is impossible. This isn't true! The N-9 research data don’t suggest that a developing safe and effective microbicides is impossible -- only that N-9 probably is not one of them.